Hengrui Pharmaceutical announced that the company's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received the SHR-3201 injection “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and will conduct clinical trials in the near future. The application for this drug is Alzheimer's disease. It is a treatment developed independently by the company. It can remove biomarkers of brain diseases and delay cognitive decline. No similar drugs have been approved for marketing at home or abroad. Up to now, the project has invested about 48.8 million yuan in R&D. Subsequent clinical trials of the drug need to be carried out and approved before it can be produced and marketed. There is uncertainty.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.